GGrantIndex
← Leaderboards

Bijay Mukherji

University Of Connecticut Sch Of Med/Dnt

$4,733,481
Attributed
$4,733,481
Total exposure
14
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $502K · FY200512
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12

Funding mix

By agency

NIH$4,733,481 · 14

By mechanism

R01$4,683,771 · 4
M01$49,710 · 10

Top collaborators

No co-investigators on record.

Most similar at University Of Connecticut Sch Of Med/Dnt

Same institution · by research overlap

Others in their field

Top investigators on “Melanoma

Research focus

MelanomaDendritic CellsClinical ResearchHuman SubjectTumor AntigensHelper T LymphocyteNeoplasm /Cancer VaccineNeoplasm /Cancer ImmunotherapyApoptosisCytotoxic T LymphocyteResponseAntigensGenerationsNeoplasm /Cancer ImmunologyLifeBaseDesignMediatingEpitopesIn VivoCancer VaccinesMhc Class I AntigenImmunotherapyLymphocyte Activation

Grant awards (39)

TCR Engineered CD4 Cells as Helpers in Tumor Immunity$226,056
R01 · FY2012 · CA · contact PI
TCR Engineered CD4 Cells as Helpers in Tumor Immunity$226,056
R01 · FY2011 · CA · contact PI
Rescuing CTL from Activation Induced Death$255,082
R01 · FY2010 · CA · contact PI
TCR Engineered CD4 Cells as Helpers in Tumor Immunity$233,650
R01 · FY2010 · CA · contact PI
Rescuing CTL from Activation Induced Death$255,082
R01 · FY2009 · CA · contact PI
TCR Engineered CD4 Cells as Helpers in Tumor Immunity$246,900
R01 · FY2009 · CA · contact PI
Rescuing CTL from Activation Induced Death$255,082
R01 · FY2008 · CA · contact PI
AICD (ACTIVATION INDUCED CELL DEATH)$7,778
M01 · FY2008 · RR · contact PI
Rescuing CTL from Activation Induced Death$255,082
R01 · FY2007 · CA · contact PI
DENDRITIC CELLS (DC) CROSSTALK$1,725
M01 · FY2007 · RR · contact PI
Rescuing CTL from Activation Induced Death$262,700
R01 · FY2006 · CA · contact PI
DENDRITIC CELLS (DC) CROSSTALK$4,625
M01 · FY2006 · RR · contact PI
LEUKAPHERESIS IN SELECTED PATIENTS$289
M01 · FY2006 · RR · contact PI
T CELL RESPONSE TO GENETICALLY ENGINEERED AND MATURED DENDRITIC CELLS$289
M01 · FY2006 · RR · contact PI
DC Th Crosstalk in CTL Response to Mart 1$210,613
R01 · FY2005 · CA
DC CROSSTALK$5,610
M01 · FY2005 · RR
DC Th Crosstalk in CTL Response to Mart 1$210,613
R01 · FY2004 · CA
DC Crosstalk$4,967
M01 · FY2004 · RR
Melanoma Vaccine Phase II$764
M01 · FY2004 · RR
T Cell Response to Genetically engineered and Matured DC$191
M01 · FY2004 · RR
T CELL RESPONSE TO GENETICALLY ENGINEERED AND MATURED DC$248,681
R01 · FY2003 · CA
DC Th Crosstalk in CTL Response to Mart 1$210,613
R01 · FY2003 · CA
T CELL RESPONSE TO GENETICALLY ENGINEERED AND MATURED DC$242,480
R01 · FY2002 · CA
DC Th Crosstalk in CTL Response to Mart 1$210,250
R01 · FY2002 · CA
MACROPHAGE BASED MELANOMA VACCINE$0
M01 · FY2002 · RR
T CELL RESPONSE TO GENETICALLY ENGINEERED AND MATURED DC$235,761
R01 · FY2001 · CA
DC Th Crosstalk in CTL Response to Mart 1$209,160
R01 · FY2001 · CA
PEPTIDE AND APC BASED MELANOMA VACCINE$153,893
R01 · FY2001 · CA
MACROPHAGE BASED MELANOMA VACCINE$4,361
M01 · FY2001 · RR
MACROPHAGE BASED MELANOMA VACCINE$0
M01 · FY2001 · RR
MACROPHAGE BASED MELANOMA VACCINE$0
M01 · FY2001 · RR
PEPTIDE AND APC BASED MELANOMA VACCINE$307,125
R01 · FY2000 · CA
T CELL RESPONSE TO GENETICALLY ENGINEERED AND MATURED DC$228,892
R01 · FY2000 · CA
MACROPHAGE BASED MELANOMA VACCINE$19,111
M01 · FY2000 · RR
Peptide &APC based melanoma vaccine$0
M01 · FY2000 · RR
Peptide &APC based melanoma vaccine$0
M01 · FY2000 · RR
Peptide &APC based melanoma vaccine$0
M01 · FY2000 · RR
MACROPHAGE BASED MELANOMA VACCINE$0
M01 · FY2000 · RR
MACROPHAGE BASED MELANOMA VACCINE$0
M01 · FY2000 · RR